{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.7.', 'Appendix 7: Modified List of Highly Effective Methods for', 'Avoiding Pregnancy in FRP and Collection of Pregnancy', 'Information', '12.7.1.', 'Modified List of Highly Effective Methods for Avoiding Pregnancy', 'in Females of Reproductive Potential (FRP)', 'The list does not apply to FRP with same sex partners or for subjects who are and will', 'continue to be abstinent from penile-vaginal intercourse on a long term and persistent', 'basis, when this is their preferred and usual lifestyle. Periodic abstinence (e.g. calendar,', 'ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable', 'methods of contraception.', '1.', 'Contraceptive subdermal implant', '2.', 'Intrauterine device or intrauterine system', '3. Combined estrogen and progestogen oral contraceptive [Hatcher, 2011]', '4.', 'Injectable progestogen [Hatcher, 2011]', '5.', 'Contraceptive vaginal ring [Hatcher, 2011]', '6.', 'Percutaneous contraceptive patches [Hatcher, 2011]', '7.', 'Male partner sterilization with documentation of azoospermia prior to the female', \"subject's entry into the study, and this male is the sole partner for that subject\", '[Hatcher, 2011]. The documentation on male sterility can come from the site', \"personnel's: review of subject's medical records, medical examination and/or semen\", 'analysis, or medical history interview provided by her or her partner.', 'These allowed methods of contraception are only effective when used consistently,', 'correctly and in accordance with the product label. The investigator is responsible for', 'ensuring that subjects understand how to properly use these methods of contraception.', '12.7.2.', 'Collection of Pregnancy Information', 'Investigator will collect pregnancy information on any female subject, who becomes', 'pregnant while participating in this study', 'Information will be recorded on the appropriate form and submitted to GSK within 2', \"weeks of learning of a subject's pregnancy.\", 'Subject will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on mother and infant, which will be', 'forwarded to GSK. Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', '88']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female subject who becomes pregnant while participating', 'will be withdrawn from the study', '89']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.8.', 'Appendix 8: Country Specific Requirements', 'In Canada only, additions were made to Section 7.4.1 and Appendix 4 to comply with', 'Health Canada guidelines concerning the requirement of pharmaceutical manufacturers to', 'expeditiously report domestic cases of unusual failure in efficacy (UFIE) for new drugs', 'to the Marketed Health Products Directorate (MHPD) within 15 days of first notification.', '90']\n\n###\n\n", "completion": "END"}